Web posted by PAF
Patient Advocate Foundation has been notified that the drug supply shortage of the pharmaceutical product DOXIL® will no longer affect provider and patients who rely on that specific medication to address their medical conditions.
According to a release provided by Janssen Products, LP, DOXIL will be restored to full access for physicians and their patients beginning October 22, 2012 through normal and authorized distributors.
Patient Advocate Foundation is pleased that this issue will no longer serve as a barrier for patients and providers who seek DOXIL as part of their treatment plans. To read about previous statements by PAF and National Patient Advocate Foundation (NPAF) regarding this drug shortage, as well as shortages occurring in the marketplace with other pharmaceuticals, please view:
PAF Statement on Drug Shortages
NPAF Addresses Drug Shortages